SEPN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SE

Mkt Cap

$1.70B

Volume

199.91K

Next Earnings

November 9th

Loading chart

SE

SEPNSepterna, Inc. Common Stock

SEPN

Pay with—

Available Balance0.00

SE

Mkt Cap

$1.70B

Volume

199.91K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Septerna, Inc. announced the grant of 275,000 non-qualified stock options to Dr. Rajiv Patni, the company's newly appointed Chief Medical Officer. The options have an exercise price of $37.37 per share, a ten-year term, and vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months.GlobeNewswire Inc. · Sep 10, 2026

Septerna to Participate in Upcoming Investor ConferencesSepterna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company focused on GPCR drug discovery, announced participation in two investor conferences in September 2026. The company also appointed industry veteran Rajiv Patni, M.D., as Chief Medical Officer. Septerna is advancing its Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist, with SAD/MAD data expected in Q1 2027.GlobeNewswire Inc. · Sep 1, 2026

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical OfficerSepterna, Inc. announced the appointment of Dr. Rajiv Patni as Chief Medical Officer. Dr. Patni brings over 25 years of biopharmaceutical experience and has contributed to 10 regulatory approvals across multiple companies. He joins from Judo Bio where he served as CEO and will lead Septerna's clinical development efforts for its GPCR-targeted drug pipeline.GlobeNewswire Inc. · Aug 25, 2026

Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?Septerna's Chief People Officer Samira Shaikhly sold 11,798 shares worth approximately $355,000 on May 26, 2026, reducing her direct holdings by 93.7%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025, indicating a non-discretionary transaction designed to avoid insider trading accusations. Despite the large insider sale, the company reported positive clinical trial progress and maintains strong cash reserves of $522.1 million, sufficient to fund operations into 2029.The Motley Fool · Jul 5, 2026

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?Septerna SVP Daniel D. Long exercised and sold 15,000 shares for ~$533,000 on June 22, 2026, reducing his direct holdings by 13.46%. The analyst suggests this appears to be routine income supplementation rather than a loss of confidence, as Long retains 96,412 shares and 36,000 unexercised options. Septerna, a clinical-stage biotech developing GPCR-targeted therapies, has shown positive phase 1 results for SEP-631 and maintains partnerships with Novo Nordisk.The Motley Fool · Jun 30, 2026

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategySepterna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator for treating mast cell-driven diseases. The drug demonstrated robust, dose-dependent inhibition of icatibant-induced skin wheal formation with complete inhibition at 10 mg once-daily, was well-tolerated with an adverse event profile comparable to placebo, and showed a pharmacokinetic profile supporting once-daily dosing. The company plans to initiate Phase 2b development in chronic spontaneous urticaria in the second half of 2026.GlobeNewswire Inc. · Mar 1, 2026

Septerna to Participate in 8th Annual Evercore Healthcare ConferenceSepterna, a clinical-stage biotechnology company specializing in GPCR drug discovery, will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, presenting via live webcast.GlobeNewswire Inc. · Nov 25, 2025

Analysts Think These Stocks Could More Than Double in ValueAnalysts believe three healthcare stocks - Septerna Inc, Intellia Therapeutics, and Novavax - have the potential to at least double in price, although they carry varying levels of risk.Investing.com · May 23, 2025

Is It Time to Buy the Dip in Novo Nordisk Stock?Novo Nordisk stock is down nearly 50% in 2025 despite a double beat in its quarterly earnings. Analysts believe the stock has significant upside, but factors like increased competition and a new executive order on drug pricing could weigh on the stock in the short term.Investing.com · May 15, 2025

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of InvestorsKirby McInerney LLP is investigating potential claims against Septerna, Inc. (NASDAQ:SEPN) after the company announced the discontinuation of a clinical trial for its hypoparathyroidism treatment due to unexpected severe cases of elevated unconjugated bilirubin.GlobeNewswire Inc. · Feb 19, 2025

to start trading

SE

SEPNSepterna, Inc. Common Stock

SEPN

Pay with—

Available Balance0.00

Your PositionYou don't own any SEPN yet.

Related Tickers

Earnings